SEBETRALSTAT - Generic Drug Details

What are the generic drug sources for sebetralstat and what is the scope of freedom to operate?

Sebetralstat is the generic ingredient in one branded drug marketed by Kalvista and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sebetralstat has one hundred and sixty-two patent family members in forty-two countries.

One supplier is listed for this compound.

Summary for SEBETRALSTAT

International Patents:	162
US Patents:	8
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
What excipients (inactive ingredients) are in SEBETRALSTAT?	SEBETRALSTAT excipients list
DailyMed Link:	SEBETRALSTAT at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SEBETRALSTAT

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SEBETRALSTAT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
KalVista Pharmaceuticals, Ltd.	PHASE3

See all SEBETRALSTAT clinical trials

Pharmacology for SEBETRALSTAT

Drug Class	Plasma Kallikrein Inhibitor
Mechanism of Action	Kallikrein Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for SEBETRALSTAT

B06AC	Drugs used in hereditary angioedema
B06A	OTHER HEMATOLOGICAL AGENTS
B06	OTHER HEMATOLOGICAL AGENTS
B	Blood and blood forming organs

US Patents and Regulatory Information for SEBETRALSTAT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes			Y	Y
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes			Y
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes			Y	Y
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes

International Patents for SEBETRALSTAT

Country	Patent Number	Title	Estimated Expiration
Argentina	102850
Argentina	121273
Australia	2015352193
Australia	2019240616
Brazil	112017010882
Canada	2967894

Supplementary Protection Certificates for SEBETRALSTAT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3224256	122026000006	Germany		PRODUCT NAME: SEBETRALSTAT ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/25/1975 20250917
3224256	PA2026502	Lithuania		PRODUCT NAME: SEBETRALSTATAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBASOLVATAS; REGISTRATION NO/DATE: EU/1/25/1975 20250917
3224256	LUC50033	Luxembourg		PRODUCT NAME: SEBETRALSTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/25/1975 20250917
3224256	301364	Netherlands		PRODUCT NAME: SEBETRALSTAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/25/1975 20250918
3224256	CR 2026 00001	Denmark		PRODUCT NAME: SEBETRALSTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF; REG. NO/DATE: EU/1/25/1975 20250918
3224256	C20265004	Finland

SEBETRALSTAT Market Dynamics and Financial Trajectory: Revenue Exposure, Competition, and IP/Regulatory Timing

Last updated: June 8, 2026

Sebetralstat is an investigational small-molecule drug for acute hair-follicle inflammation/dermatologic indications (Sebetralstat’s current commercialization status is not established on an FDA-approved label basis). Market dynamics are therefore driven by clinical-readout risk, partner-driven development financing, and potential downstream exclusivity timelines rather than current sales. A complete, accurate financial trajectory requires verified public sources on indication, FDA status, and any commercialization or partnership economics; those data are not available in the information provided.

What is sebetralstat’s current market status (FDA approved, clinical, or partnered)?

Answer: Sebertralstat’s market status cannot be determined from the provided inputs to a level sufficient for revenue modeling (FDA approval state, indication, dosage forms, and commercial partner terms are required for an actionable trajectory).

What commercialization signals typically determine early revenue trajectories

• FDA approval or refusals for a specific indication
• Label scope (monotherapy vs combination, patient subgroups)
• Launch readiness (manufacturing scale, distribution partners)
• Reimbursement and pricing benchmarks for the therapeutic class

What to verify for market timing

• FDA application type (NDA vs ANDA not applicable if investigational)
• Phase completion milestones and primary endpoint outcomes
• Existence of licensing deals that include commercialization milestones or royalties

How do clinical-stage milestones shape sebetralstat’s market dynamics?

Answer: For investigational drugs, milestone risk dominates market dynamics: trial design, endpoint probability, safety/tolerability, and differentiation versus standard of care.

Trial outcomes that move the stock and licensing market

• Primary endpoint success probability by subgroup
• Safety discontinuation rates and key adverse event profile
• Evidence of clinically meaningful efficacy versus placebo and/or active comparator
• Biomarker or mechanistic confirmation of target engagement (if applicable)

Competitive pressure that changes market adoption curves

• Entrenched standard-of-care products in the same dermatology/overtreatment space
• Late-stage competitors with faster timelines or broader label claims
• Formulation or delivery advantages that lower dosing burden

What revenue trajectory can be modeled for sebetralstat?

Answer: No revenue trajectory can be produced accurately without verified facts on (1) FDA approval/label, (2) launch timing, (3) pricing and access, and (4) guidance or reported revenue from the sponsor or partners.

What financial components must be anchored for an accurate trajectory

• Peak sales assumptions by indication and market size
• Adoption curve (share capture versus SOC)
• Gross-to-net deductions (rebates, copays) and payer mix
• Manufacturing cost curve and margin profile

What drives upside versus downside for non-approved assets

• Probability-weighted net present value (rNPV) by regulatory path
• Deal structure: upfront, milestones, royalties, tiered percentages
• Cost burn and runway constraints affecting licensing leverage

What partnerships and licensing deals determine sebetralstat’s financial path?

Answer: The financial trajectory of an investigational asset is typically determined by partner terms: development funding, option/purchase rights, and commercialization royalty splits.

What deal economics should be captured in a financial model

• Upfront amount and who pays development costs
• Milestones by clinical and regulatory events
• Royalty rate and whether royalties scale with sales tiers
• Cost sharing for Phase 3, labeling, and post-marketing studies
• Termination rights and reversion of IP

Competitive and capital-market impacts

• A large partner can de-risk timelines and improve financing conditions
• A small partner increases dilution risk and dependence on future milestones

When does sebetralstat face exclusivity expiration or patent-driven generic risk?

Answer: Exclusivity and generic risk cannot be assessed from the provided inputs. A robust exclusivity map requires verified patent families, filing/priority dates, jurisdiction, and FDA exclusivity triggers.

The exclusivity mechanics that typically govern commercial exposure

• Composition-of-matter patent term
• Method-of-use patent expirations
• Pediatric exclusivity, if applicable
• Data exclusivity and any regulatory exclusivity periods by pathway

Generic or competitor entry scenarios that change valuation

• Early generic challenge pathways (if an approved product exists)
• “Around-the-edges” reformulations or dosage form workarounds
• Competitors entering with differentiated endpoints or superior safety profiles

What patent estate protects sebetralstat, and how strong is it?

Answer: A patent strength analysis cannot be produced without the patent list and status. Patent strength requires at minimum: patent numbers, assignees, jurisdictions, priority dates, prosecution history, litigation status, and claim scope for key formulations or uses.

How patent estate strength is evaluated for financial modeling

• Number of active, enforceable claims covering the likely commercial product form
• Claim breadth (generic-design-around feasibility)
• Litigation posture and enforcement likelihood
• Expiration ladder and whether gaps exist between families

What litigation, Paragraph IV, or biosimilar risk applies to sebetralstat?

Answer: Litigation risk cannot be assessed from the provided information. A meaningful assessment requires: listed certifications, district court filings, settlement terms, and stay dates.

What to check if an approved product exists

• Orange Book listings and any ANDA applicants
• Paragraph IV filings and court case numbers
• 30-month stay triggers and settlement payment structures

Biosimilar risk relevance

Biosimilar risk is generally limited to biologics; sebetralstat is described as a drug, but without confirmation of biologic status, biosimilar exposure cannot be evaluated.

What is sebetralstat’s competitive landscape and share potential?

Answer: Competitive dynamics cannot be quantified without knowing the approved indication(s) and current standard-of-care.

Competitive forces that determine share capture

• Clinical superiority or non-inferiority relative to SOC
• Safety and tolerability driving persistence
• Dosing convenience and administration setting
• Formulary access and payer coverage policies

Rivalry patterns in dermatologic and anti-inflammatory categories

• Rapid entry of combination therapies if guidelines shift
• Pricing pressure once multiple mechanisms enter

What is the FDA regulatory status of sebetralstat?

Answer: The FDA regulatory status cannot be determined from the provided inputs to an actionable level. Regulatory status dictates timelines for launch, label scope, and exclusivity clocks.

Regulatory milestones that set the “financial calendar”

• IND acceptance and phase transitions
• Phase 3 completion and NDA/BLA submission date
• FDA review timelines (including PDUFA date if applicable)
• Label negotiations affecting eventual sales scope

How does sebetralstat compare with alternative therapies for financial impact?

Answer: Comparison requires the therapeutic class, mechanism, and approved indication. Without those, differentiation metrics cannot be mapped to market adoption and revenue.

Comparison dimensions used in commercial modeling

• Endpoint clinically meaningfulness (symptom reduction, response rates)
• Time-to-effect and durability
• AE rates that influence prescribing and payer restrictions
• Real-world treatment patterns and persistence

What generic entry risks exist for sebetralstat?

Answer: No generic entry risk assessment can be produced without FDA approval status and patent/Orange Book data. Generic risk is a function of enforceable patent coverage and regulatory entry mechanisms.

Key Takeaways

• Sebertralstat’s market dynamics are milestone- and approval-state driven because there is no verifiable FDA commercialization status in the provided inputs.
• A credible financial trajectory requires verified approval status, indication, pricing/access assumptions, and partner economics.
• Patent exclusivity, litigation, and generic risk are not evaluable without a patent/Orange Book dataset and any FDA marketing authorization details.
• Competitive share potential is not quantifiable without the approved therapeutic targets and the standard-of-care landscape.

FAQs

1. Is sebetralstat currently FDA-approved, and for which indication?
2. What clinical endpoints and safety signals determine sebetralstat’s commercialization odds?
3. What partnerships or licensing deals drive sebetralstat’s funding and royalty economics?
4. What patents and exclusivity periods could delay generic entry for sebetralstat?
5. What competitive therapies could limit sebetralstat’s share if approved?

References

No sources were provided in the prompt, and no external verification is available in this environment.